Ascentage Pharma Group International ASPHF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.60
- Day Range
- $2.50–2.50
- 52-Week Range
- $2.35–4.11
- Bid/Ask
- $1.85 / $3.90
- Market Cap
- $724.58 Mil
- Volume/Avg
- 310,101 / 146,756
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.49
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 583
- Website
- https://www.ascentagepharma.com
Comparables
Valuation
|
Metric
|
ASPHF
|
06628
|
02171
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 85.12 | 0.79 | 1.88 |
Price/Sales | 22.49 | 12.36 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ASPHF
|
06628
|
02171
|
|---|---|---|---|
Quick Ratio | 2.73 | 1.50 | 9.49 |
Current Ratio | 2.74 | 1.61 | 9.55 |
Interest Coverage | −9.36 | −33.53 | −174.85 |
Quick Ratio
ASPHF
06628
02171
Profitability
|
Metric
|
ASPHF
|
06628
|
02171
|
|---|---|---|---|
Return on Assets (Normalized) | −30.37% | −22.79% | −28.70% |
Return on Equity (Normalized) | −142.24% | −38.31% | −35.29% |
Return on Invested Capital (Normalized) | −35.31% | −26.22% | −35.38% |
Return on Assets
ASPHF
06628
02171
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cypkjwsd | Msgl | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zqpfvcm | Njjgnk | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ntghkfdp | Ngvvz | $103.7 Bil | |
MRNA
| Moderna Inc | Hzpgpcdf | Qfln | $47.9 Bil | |
ARGX
| argenx SE ADR | Gmzwgfx | Vgqfz | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Tnsfpgllb | Dspr | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fdmvsfx | Nwgsm | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fbtzszb | Bbhqnl | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Chgzglrklt | Nmxgsf | $12.8 Bil | |
INCY
| Incyte Corp | Tfbfvcj | Jnkvz | $12.1 Bil |